Oppenheimer Reiterates Outperform on Immunocore Hldgs, Raises Price Target to $87
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Justin Kim has reiterated an Outperform rating on Immunocore Holdings (NASDAQ:IMCR) and increased the price target from $85 to $87.

February 29, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Justin Kim has reiterated an Outperform rating on Immunocore Holdings and raised the price target from $85 to $87.
The reiteration of an Outperform rating combined with an increased price target by a reputable analyst like Justin Kim suggests a strong bullish sentiment towards Immunocore Holdings. This is likely to instill confidence in current and potential investors, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100